Shanghai Henlius Deal History & Licensing Activity
Shanghai Henlius is a biotech headquartered in China. Over the past three years, Shanghai Henlius has been involved in 8 licensing and acquisition transactions, with a primary focus on Antibodies (5 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
4
Active Trials
50
Top Modality
Antibodies
Focus Area
Solid Tumors
Shanghai Henlius Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Shanghai Henlius in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| T-cell engager program | Henlius | Bispecific Antibodies | Unknown | license | Sep 24, 2026 |
| Undisclosed | Shanghai Henlius Biotech, Inc. | Bispecific Antibodies | Discovery | collaboration | Sep 23, 2026 |
| HLX05-N, HLX16, belimumab biosimilar, HLXTE-HAase1001 | Sandoz | Antibodies | Preclinical | collaboration | Aug 17, 2026 |
| Biosimilar products (3 initial biosimilars plus option on 4th asset) | Sandoz | Other | Unknown | option | Aug 17, 2026 |
Shanghai Henlius Pipeline Focus
Therapeutic areas and modalities where Shanghai Henlius is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Shanghai Henlius Clinical Pipeline
Shanghai Henlius has 50 active clinical trials across 7 development phases.
1
Early Phase 1
1
Not Applicable
15
Phase 1
2
Phase 1/2
21
Phase 2
5
Phase 2/3
5
Phase 3
See How Your Asset Matches Shanghai Henlius's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Shanghai Henlius Licensing & Deal Activity
Shanghai Henlius is a biotech company based in China that has been actively engaged in licensing transactions across the biopharma landscape. With 8 deals over the past three years, Shanghai Henlius ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Shanghai Henlius include Solid Tumors (39 deals and trials), Other (6 deals and trials), Oncology (6 deals and trials), and Hematological Malignancies (2 deals and trials). In terms of modality, Shanghai Henlius has shown particular interest in antibodies, bispecific antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Shanghai Henlius and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Shanghai Henlius's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.